Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
Open Access
- 20 May 2023
- journal article
- editorial
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 29, 125-126
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences & Peking Union Medical College
This publication has 10 references indexed in Scilit:
- Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacyScience Immunology, 2023
- Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenovirusesMolecular Therapy-Oncolytics, 2023
- The emerging field of oncolytic virus-based cancer immunotherapyTrends in Cancer, 2022
- Optimal timing of PD-1 blockade in combination with oncolytic virus therapySeminars in Cancer Biology, 2022
- Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoidsJournal for ImmunoTherapy of Cancer, 2021
- Mechanisms of Therapeutic Antitumor Monoclonal AntibodiesCancer Research, 2021
- Evolving Status of Clinical Immunotherapy with Oncolytic AdenovirusClinical Cancer Research, 2021
- Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell KillingCancer Immunology Research, 2015
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisCancer Cell, 2015
- Oncolytic virotherapyNature Biotechnology, 2012